CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
Portal Innovation's 30,000-square-foot Helix Park lab space is open for business. Photo via Portal Innovations/X

Innovative life science hub opens doors of Houston location, welcomes inaugural startups

ready to grow

A new life science-focused venture capital engine has officially opened offices in Houston.

Portal Innovations moved into a space at Helix Park in October. The offices are led by executive director Monique Knighten.

Knighten has been in Houston for 16 years, since she was a postdoc at the University of Texas Institute for Molecular Medicine. “It's like a lot of us. We come for a specific reason, and then we just find reasons to stay,” she says.

And now, that reason is to push the emerging Houston ecosystem forward by helping early-stage startups to build themselves toward success. Portal does that partly by providing capital, but besides cash investments, emerging companies need a physical infrastructure where their work can happen. They also need great people to support their cause at every step of development. To that end, networking and convening with beneficial people is key for Portal.

With locations already in Chicago, Boston and Atlanta, why did Portal choose Houston?

“If you take a look at where lots of scientific publications are coming from, if you look at where a lot of technology that eventually becomes commercialized, a lot of it will come initially from labs that are right here in Houston,” says Knighten. “Houston also has a great quality of life. That's really important so that startups need to be able to have a place where they can have their teams.”

And who has joined Portal in its 30,000-square-foot Helix Park lab space? March Biosciences, a cancer-focused cell therapy startup; Crossbridge Bio, responsible for a cancer therapeutic that just closed a $10 million seed round; Artidis, which is personalizing cancer diagnosis thanks to a new nanomedical biomarker technology; Spanios, which has created human model systems to help researchers better identify therapeutic options for solid tumors; Stingray Therapeutics, a cancer immunotherapy company working on metastatic or advanced solid tumors; Remunity Therapeutics, an immuno-oncology startup developing immune-stimulating antibody-drug conjugates that reactivate anti-tumor immune response; and Phiogen, which is doing promising work in the world of non-antibiotic anti-infectives.

The Cancer Focus Fund, an oncology-focused investment fund in partnership with The University of Texas MD Anderson Cancer Center is also sharing space with the burgeoning biomedical companies.

Even Texas Medical Center CEO Bill McKeon is excited to greet Portal.

“In Portal, we have a partner with a proven track record of leveraging venture capital funding, expert partners and strong programming to support dynamic, entrepreneurial businesses at pivotal moments of their growth. We look forward to building on our collective expertise and shared vision to further support the breakthroughs of early-stage life science ventures,” he says on the company’s website.

By working with Portal, each of the companies will benefit not only from Knighten’s expertise i building teams gathered from her time at Sartorius Stedim Biotech and decade with Miltenyi Biotec, but also that of the other Portal teams. Working on a national scale also gives the brands opportunities for national exposure. Just one more way, Houston’s ecosystem is continuing to move the needle both for the healthcare companies in it and the patients who will one day benefit.

This week's roundup of Houston innovators includes Michael Torres of CrossBridge Bio, Aileen Allen of Mercury, and Ryan Reisner of SeekerPitch. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across therapeutics, venture capital, and HR software.

Michael Torres, CEO of CrossBridge Bio

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via crossbridgebio.com

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT. Continue reading.

Aileen Allen, venture partner at Mercury

Aileen Allen joined Mercury as venture partner and is on the board of the Houston Angel Network. Photo courtesy of Mercury

When Aileen Allen was contemplating a big career move — swapping sides of the table from tech company to venture investor — she was motivated by driving gender and experience diversity amongst decision makers.

"I've worked for VC-backed companies for most of my career and had the opportunity as an executive to be in the boardroom during that time," she says on the Houston Innovators Podcast. "One of my takeaways was that very few of my board members looked like me. I had one or two women on any of my boards at a time in totality, and very few of my board members had been operators."

"I'd really like to change that, and I'd like there to be better representation and diversification in the boardroom," she adds. Continue reading.

Ryan Reisner, president and founder of SeekerPitch

Ryan Reisner is the\u00a0president and founder of SeekerPitch and The Reisner Group. Photo via LinkedIn

Confident job seekers have mostly been of the mindset that if they can just get in front of an employer, they can sell themselves into an offer for the open position. The obstacle then, is getting through the screening process to get an actual interview.

Until recently, the price of admission for starting or progressing in a desired career was a resume and cover letter stellar enough to catch the eye of the human resources and recruiting team. Outside of being buried in the immense pile of resumes recruiters do not have the bandwidth to get to, standing out in the sea of candidates can be daunting.

Resumes do not tell the full story as it is and it’s almost impossible for applicants to put their potential, soft skills and work personality into a document to be reviewed. So, what’s the solution?

It is a multi-layered problem, which requires a multi-layered solution, but one of the options gaining steam in the recruitment space is provided by SeekerPitch, a Houston-based HR technology platform utilizing generative AI to make hiring and interviewing more efficient.

“I've noticed that there's a ton of people that slip through the cracks,” says Ryan Reisner, president and founder of SeekerPitch and The Reisner Group. “And we spend all our time interviewing people to see if they have the soft skills. Resumes are hard skills. And now with AI, anybody can build the same exact resume. Everybody can say they have communication skills, leadership skills, and a lot of people say they have those." Continue reading.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Venus Aerospace closes $91M funding round to scale hypersonic engine

flight funding

Houston-based Venus Aerospace has closed a $91 million Series B round and plans to scale the production of its hypersonic engine.

The round was led by Houston-based Mercury Fund with participation from Lockheed Martin Ventures, MESH, PEAK6, Draper Associates, Starboard Star Venture Capital, Green Sands Equity and other investors, according to a news release.

The investment comes about a year after Venus completed the first U.S. flight test of its high-thrust rotating detonation rocket engine (RDRE). The engine is expected to enable vehicles to travel four to six times the speed of sound from a conventional runway and is about 15 percent more efficient than traditional alternatives, according to the company.

Venus Aerospace says the latest round of funding will allow it to move the RDRE from demonstration to deployment and meet customer requirements for the near-term defense and space industries. The company says that the reusable RDRE is designed with a "common propulsion architecture" that can work for multiple industries and mission types.

“This financing marks an important step in moving Venus from breakthrough demonstration to scaled capability,” Sassie Duggleby, co-founder and CEO, said in the news release. “Our customers need propulsion systems that go farther, can be produced reliably and are built on supply chains they can trust. We are advancing that capability with American engineering and manufacturing talent to strengthen U.S. defense, expand space access and support the future of high-speed flight.”

Venus Aerospace raised a $20 million Series A in 2022, led by Wyoming-based Prime Movers Lab. At the time, the company said it would put the funding toward three main technologies: a next-generation rocket engine, aircraft shape and leading-edge cooling system.

The company also picked up an investment from Lockheed Martin Ventures, the investment arm of aerospace and defense contractor Lockheed Martin, in November 2025—in addition to funding from other investors over the years.

“Since our initial investment, Venus has progressed very quickly in its technology development," Chris Moran, vice president and general manager of Lockheed Martin Ventures, added in the release. "Our reinvestment in Venus recognizes Venus’ accomplishments to date and focus on speed to manufacture, cost management and reduction of supply chain constraints. Venus is working effectively to position its propulsion system for the production scale required by defense programs.”

"Venus is exactly the kind of company Houston capital should be backing," Blair Garrou, co-founder and managing partner at Mercury Fund, added in the release. "It combines multiple frontier technologies, domestic manufacturing and clear commercial and national security relevance. We believe this team is positioned to lead an important new chapter in defense and space, and we are proud to support a company building breakthrough technology here in Texas."

Venus Aerospace and Houston clean tech startup Vaulted Deep were named to the World Economic Forum's Technology Pioneers community earlier this summer. Read more here.

Intuitive Machines lands $148M as part of NASA Moon Base funding

to the moon

Houston-based Intuitive Machines has been awarded $148.3 million to deliver its Nova-C lander to the moon by 2028. The funding is part of $600 million that NASA recently awarded to three companies as part of the agency’s Moon Base Program.

The contracts aim to support sustained human presence and commercial operations on the Moon. Austin-based Firefly Aerospace was awarded $144.2 million by NASA for one mission and Pittsburgh-based Astrobotic netted $297.9 million for two lunar landings. Intuitive Machine's award is the company's sixth task order under NASA's Commercial Lunar Payload Services (CLPS) program.

“We’re building a proving ground for Moon Base operations,” Ryan Stephan, NASA’s Moon Base acting director of cargo landers, said in a news release. “Accelerating our Moon mission ordering cadence and launch opportunities enable us to move quickly to learn, iterate, and improve.”

Under the latest task order, Intuitie Machines will deliver three scientific and operational payloads to the moon, which include a:

  • Linear Energy Transfer Spectrometer (LETS) radiation monitor to gather critical environmental safety data
  • Advanced stereo cameras to analyze surface-plume interactions (SCALPSS)
  • Laser retroreflector array (LRA) for precise cislunar positioning

The funding breakdown includes a $68.6 million base contract and a $79.7 million performance incentive for Intuitive Machines.

The company says the funding will allow it to create a standardized and repeatable "lunar utility pipeline" for delivering cargo to the moon.

"We are shifting the paradigm from custom aerospace engineering to commercial mass production of lunar infrastructure," Steve Altemus, CEO of Intuitive Machines, said in a separate news release. "Our flight-proven Nova-C platform allows us to build, test, and deploy multiple landers in parallel using Industry 4.0-powered manufacturing. This contract directly advances our core mission to provide persistent, reliable, and commercial baseline of transport, connectivity, and operations that allows our customers to stay longer and achieve more on the Moon."

NASA also shared that it is exploring plans to send PROMISE, a rover based on the Mars Perseverance and Curiosity rovers, to the moon and it plans to seek proposals for additional lunar lander missions, technology demonstrations, a communications and navigation satellite network, and new science payloads to support its lunar outpost. NASA is developing its Moon Base near the lunar South Pole. The agency expects it to come to fruition sometime after 2032.

Intuitive Machines had received its last CLPS award for $180.4 million in March 2026. It will be the first mission to utilize the company's larger cargo lunar lander, Nova-D. The company was also recently awarded a $1 million grant from Maryland Gov. Wes Moore to expand its robotics operations in the state.

UT team develops wearable technology for atmospheric water harvesting

In The Air

Engineers at the University of Texas at Austin have developed a prototype jacket that harvests clean drinking water directly from the atmosphere, and it works even in the driest desert conditions.

The research, published in Science Advances, marks the latest milestone in nearly a decade of work by materials scientist and chair professor Guihua Yu and his team at the Cockrell School of Engineering's Walker Department of Mechanical Engineering and Texas Materials Institute. The wearable technology marks a significant leap: instead of a bulky, stationary machine, this jacket does the work.

Photo courtesy of UT Austin

"We have been working on atmospheric water harvesting technology for a number of years," Yu says. "This current version is even more wearable. We're transitioning from conventional, more stationary water harvesting to something truly portable and personal."

Yu's lab first published work on hydrogel-based water harvesting around 2019, and the jacket is the latest evolution of that platform, now called AirGel. Last year, the broader AirGel invention won the top prize in the graduate category of the National Collegiate Inventors Competition.

The jacket is woven with specially engineered hydrogel fibers; ultra-porous materials that attract and absorb moisture from the surrounding air much like a household desiccant. Unlike a desiccant, the material doesn't require intense heat to release that water. The hydrogel is thermally responsive, meaning a modest rise in temperature — even from mild solar heating — is enough to release the water it has captured.

Condenser test in AustinSo, somebody would be wearing the jacket, or perhaps carrying this gel-like textile as a blanket, as it passively absorbs moisture from the air. Then they would detach the textile panels and place them into a small, portable collector unit; essentially a compact heater. The water evaporates out of the textile, condenses inside the collector, and drips out as clean, drinkable water.

"It immediately becomes drinkable because it already goes through the distillation process," Yu explains.

In trials, the jacket produced between 400 and 900 milliliters of water per day depending on humidity, or roughly 14-30 ounces, nearly a quart, depending on the air's humidity. With one kilogram of the textile, the researchers found they could generate approximately 3.7-4 liters of water in arid conditions, and potentially double that in humid ones. So far, the team has tried the jacket out in very dry, semi-dry, and humid areas, and the jacket was able to pull water from each climate.

Lead researcher Chuxin Lei, a postdoctoral researcher on Yu's team and co-author on the paper, says the goal was to rethink who this technology could serve.

Portable bag contents

"Many current [atmospheric water harvesting] systems are still built as rigid or stationary platforms, making them less suitable for people who are moving, working outdoors, or operating in some remote environment. This lead us to ask whether we could build a water harvesting system that could become more like clothing — light, wearable, flexible, and naturally suited for personal use," Lei says.

The potential applications are wide-ranging. Yu's team has previously worked with the Department of Defense on water solutions for soldiers, where water logistics can be dangerous and costly. The technology could also serve hikers, emergency responders, disaster relief workers, and agricultural and field workers. Anyone who needs clean water on the go and far from infrastructure.

The team also sees a potential future where the technology complements large-scale centralized water systems rather than replacing them.

"Our solution cannot be a universal solution for all," Yu acknowledges. "But I think it's an extremely important alternative."

For now, the jacket is still a laboratory prototype, but Yu and Lei are optimistic. With the right industry partnerships, they say, the technology could realistically reach commercial scale within three to five years.

---

This article originally appeared on CultureMap.com, written by Natalie Grigson.